Although ginsenoside-Rg18, a novel dammarane-type triterpene saponin, and panaxydol, a polyacetylenic compound, derived from Panax ginseng roots have been reported to inhibit the growth of cancer cells, the underlying molecular mechanisms for the anti...
Although ginsenoside-Rg18, a novel dammarane-type triterpene saponin, and panaxydol, a polyacetylenic compound, derived from Panax ginseng roots have been reported to inhibit the growth of cancer cells, the underlying molecular mechanisms for the anti-proliferative effects of these compounds in the A549 non-small cell lung cancer (NSCLC) cells were not determined. Treatment of A549 cells with ginsenoside-Rg18 or panaxydol induced cell cycle arrest at G1 phase. These cell cycle arrest were accompanied by down-regulation of the, cyclin-dependent kinase/cyclin (CDK)2, CDK4, CDK6, cyclin D1, cyclin D2 and cyclin E and up-regulation of cyclin-dependent kinase inhibitor p21CIP1/WAF1 and p27KIP1 involved in G1 arrest, and decrease in the phosphorylated form of retinoblastoma protein. ginsenoside-Rg18 treatment caused intracellular accumulation of reactive oxygen species (ROS), whereas it dosedependently inhibited p38, JNK and p65 phosphorylation. However, panaxydol increased NADPH oxidase (NOX) -dependent intracellular ROS and suppressed the migration of A549 cells, which correlated with the inhibition of metalloproteinase-2 (MMP-2) and MMP-9 protein expression via inhibition of MAPK/AP-1 and NF-κB signaling. These results demonstrate that the anti-proliferative effects of ginsenosideRg18 and panaxydol are closely linked to the regulation of G1 arrest in human A549 lung cancer cells.